Navigation Links
Onyx Pharmaceuticals to Present at BIO CEO & Investor Conference
Date:2/6/2008

EMERYVILLE, Calif., Feb. 6 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will present at the BIO CEO & Investor Conference on Wednesday, February 13, at 11:00 a.m. Eastern Time. Interested parties may access a live webcast of the presentation at: http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=ONXX&item_id=17524 28

It is recommended that listeners log on 15 minutes early in order to register and download any necessary software. For those unable to listen to the live webcast, a recorded replay of the presentation will be available within 24 hours of the completion of the presentation through March 13, 2008.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer by changing the way cancer is treated(TM). The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar(R) (sorafenib) tablets, a small molecule drug. Nexavar is currently approved for the treatment of advanced kidney cancer and for the treatment of liver cancer. Additionally, Nexavar is being investigated in several ongoing trials in non-small cell lung cancer, melanoma, breast cancer, and other tumor types. For more information about Onyx, visit the company's website at: http://www.onyx-pharm.com.

Nexavar(R) (sorafenib) tablets is a registered trademark of Bayer Pharmaceuticals Corporation.


'/>"/>
SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related biology technology :

1. Idenix Pharmaceuticals to Present at BIO CEO & Investor Conference
2. Meditrina Pharmaceuticals, Inc. Announces Exclusive Global License Agreement With AstraZeneca
3. Arena Pharmaceuticals to Present at the BIO CEO & Investor Conference
4. SGX Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
6. Memory Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
7. MiddleBrook Pharmaceuticals to Present at BIO CEO & Investor Conference 2008
8. Celator(R) Pharmaceuticals to Present at 10th Annual BIO CEO and Investor Conference
9. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
10. Anthera Pharmaceuticals Forms Scientific Advisory Board
11. Vion Pharmaceuticals Adds William Hahne, M.D. to Senior Management Team

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)... Spectrum Blue Steel is emerging as... on the planet. Through the efforts of True Green ... Recycling Specialist Leroy Johnston, who has been...ed that Spectrum Blue Steel is light years ahead o...r earnings because of the bi products recovered by...
(Date:12/2/2009)...re-USNewswire/ -- Nearly 600 medical research exec...ay convened to explore novel development approache...al Partnering for Cures meeting. ,, FasterC...nstitute, convened Partnering for Cures to facil... scientific discovery into an accessible therapy. ...
(Date:12/2/2009)...ember 2 , - "Bolstering B...tage" , Coinciding with the International...Republic is hosting an international conference in...iological resources in Africa. The,conference will...sters,scientific experts, private companies, repr...
(Date:12/2/2009)...Newswire/ -- S*BIO Pte Ltd today announced data pr...18, at The American Society of Hematology 51st Ann...ata will be presented on the clinical results from...ling its safety, tolerability and pharmacokinetic/...ging from 100 to 600 mg. These doses were administ...
Breaking Biology Technology:Spectrum Blue Steel partners with Famous Chemists for Procuring Profitable Applications from Garbage Using the Biosphere MKV and Electrostatic Precipitators 2Spectrum Blue Steel partners with Famous Chemists for Procuring Profitable Applications from Garbage Using the Biosphere MKV and Electrostatic Precipitators 3Medical Research Leaders Explore Novel Strategies to Expedite the Search for Cures 2Libreville International Conference 2-3 June 2010 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5
... two-thirds (67%) of Americans are generally conce...pply, according to a 2008 National Consumer Water ...adlines warning of contaminants1 (i.e. lead, radiu... stirred controversy and confusion. Consumers are ...le plastic bottles isn’t an environmentally-...
...ex, Inc. ("ChromaDex"),today announced that effect...I Acquisition, Inc. ("CDI"), the wholly-owned subs...tin Board: CDYE). The transaction,enables ChromaDe... publicly,traded, which will help it be better pos...wing marketplace. The business and operations of C...
...ction Agency Contract Will Support Development o...ial Broad-Spectrum Anti-Viral Ag...euticals, Inc. (Nasdaq: PPHM ), a clinical stage ...tibodies for the treatment of cancer and,hepatitis...ntered into a,five-year contract worth up to $44.4...
Other Biology Technology: Culligan's New Aqua-Cleer Advanced Drinking Water SystemProvides Clean, Quality Water Customized for Every Home 2 Culligan's New Aqua-Cleer Advanced Drinking Water SystemProvides Clean, Quality Water Customized for Every Home 3ChromaDex, Inc. Announces Completion of Reverse Merger With Cody Resources, Inc. 2Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hemorrhagic Fevers 2Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hemorrhagic Fevers 3Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hemorrhagic Fevers 4Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hemorrhagic Fevers 5
(Date:12/3/2009)..., N.M. Most scientists believe that staph infecti... each other to emit toxins. The signaling process ...t be present to start the process. , But the Jef...ery first stage of staph infection, when bacteria ...in a single cell and that this individual process ...
(Date:12/3/2009)...sh can undergo a personality change in warmer wate... that climate change may make some species more ag...g damselfish on Australia,s Great Barrier Reef hav... either consistently timid, or consistently bold, ...e marked as water temperatures rise. , A slight ...
(Date:12/3/2009)...rs must be included in the design of the upcoming ...nitarian crisis, according to a scientist at the U..., Dr Simon Lewis argues that at least 50% of the c...known as REDD (Reducing Emissions from Deforestati...lers directly, and their property rights assured. ...
Breaking Biology News(10 mins):Stopping MRSA before it becomes dangerous is possible, Sandia/UNM researchers find 2Stopping MRSA before it becomes dangerous is possible, Sandia/UNM researchers find 3Fish with attitude: Some like it hot 2Forest deal at Copenhagen must avoid creating 'carbon refugees' 2GPhA Says BIO Cries Wolf on Senate Biogenerics Proposal 12963 1GPhA Says BIO Cries Wolf on Senate Biogenerics Proposal 12963 2Parsippany Takes Top Honors in New Jerseys First Ever Toxic Waistlines Contest 51260 1Parsippany Takes Top Honors in New Jerseys First Ever Toxic Waistlines Contest 51260 2Parsippany Takes Top Honors in New Jerseys First Ever Toxic Waistlines Contest 51260 3Lighter Meals May Bring Longer Life 51258 1Lighter Meals May Bring Longer Life 51258 2Lighter Meals May Bring Longer Life 51258 3
...nd practicable to play soccer, shows research from...iversity of Copenhagen. , The project has receiv...ical Assessment and Research Centre of FIFA) co-fu...th benefits of football and jogging for young and ...her life style-related diseases. , The studies w...
...ecember 17, 2008)-Baruch Barry Lieber, Ph.D., prof...of Miami College of Engineering and professor of r...of Medicine, has received a grant from the Nationa...NINDS), to support research studies that offer pro...9 million grant administered over a period of five...
...University of Rochester have designed a gene that ...ells than in healthy cells., The findings may help...y: improving treatments, ability to specifically a... approach, scientists should be able to insert "se... cancer cells to kill themselves while healthy cel...
Other Biology News:University of Miami biomedical engineer 2Modified gene targets cancer cells a thousand times more often than healthy cells 2Modified gene targets cancer cells a thousand times more often than healthy cells 3
...ally encoded fluorescent sensor capable for high s...de (H2O2), one of the main ROS generated by cells....ein inserted into the regulatory domain of Escheri...es submicromolar affinity to H2O2 and at the same ...
Mouse Anti-Mouse Qa-2 Monoclonal Antibody, Alexa Fluor 647 Conjugated, Clone 695H1-9-9 from BioLegend
...for hunting and analyzing the rare transcripts usi...ing projects, microarrays, functional screenings e...r normalization of cDNA enriched with full-length ...ile most normalization methods are not well suited...
Goat Anti-Human HADHB Polyclonal Antibody, Unconjugated from IMGENEX
Biology Products: